Factors Determining the Efficacy of Botulinum Toxin for Arm Tremor in Dystonia
Status:
RECRUITING
Trial end date:
2027-05-30
Target enrollment:
Participant gender:
Summary
Tremor occurs in up to 55% of dystonia patients, which is known as dystonic tremor syndrome (DTS). Tremor can be present in the body part affected by dystonia (dystonic tremor, DT), or an unaffected body part (tremor associated with dystonia, TAWD). DTS can be treated with botulinum neurotoxin (BoNT) injections, but BoNT is effective in only about 60-70% of patients. It is unknown which patients benefit most from BoNT treatment. The investigators aim to explore the associations between clinical and pathophysiological tremor characteristics and BoNT efficacy. To do so, the investigatorswill measure clinical, electrophysiological, ultrasonographic and (functional) magnetic resonance imaging ((f)MRI) characteristics before the start of BoNT treatment and measure BoNT efficacy after three three-monthly BoNT sessions.
Phase:
PHASE4
Details
Lead Sponsor:
Radboud University Medical Center
Collaborators:
Canisius-Wilhelmina Hospital Donders Centre for Cognitive Neuroimaging